ARKG gained roughly +12% over the last 30 days, extending a broader advance of about +29% over the past quarter. The move was led by AI-enabled diagnostics and multiomics holdings, most notably Tempus AI (TEM) , on reimbursement and revenue catalysts.

ARKG gained roughly +12% over the trailing 30 days, extending a broader multi-month rebound in genomics and healthcare-innovation equities. Over the last quarter, the fund climbed approximately +26% , reflecting renewed demand for high-growth biotechnology and precision-medicine names.

ARKG advanced roughly 32% over the trailing 30 days, extending a powerful genomics and precision-medicine rally. The fund has climbed about 56% over the past three months, led by AI-driven drug discovery and strong diagnostics earnings.

The Health Care Select Sector SPDR Fund (XLV) is a passively managed, market-cap-weighted ETF (exchange-traded fund) tracking the Health Care Select Sector Index, with roughly 63 holdings and approximately $41 billion in AUM (assets under management). XLV's latest available closing price of $167.37 is about 5.7% higher than the close roughly 30 calendar days earlier, reflecting a moderate, trend-driven ETF performance advance.

The Tema Oncology ETF surged approximately 13.6% over the past 30 days, driven by a wave of landmark oncology drug approvals and positive clinical data. Over the last quarter, CANC delivered a total return of roughly 12.2%, reflecting sustained momentum across the biotechnology and precision oncology sectors.

XPH surged approximately 16% over the last 30 days, driven by broad-based strength across small- and mid-cap pharmaceutical holdings. The ETF's modified equal-weighted structure amplified gains from high-growth names such as Corcept Therapeutics , Liquidia Corp , and Definium Therapeutics .

ARKG surged approximately 25% over the last 30 days, driven by a powerful rally across genomics, precision medicine, and AI-enabled drug discovery holdings. The fund has gained roughly 54% over the last quarter, reflecting a sustained rotation into innovative healthcare and biotechnology equities.

XBI surged approximately 27% over the past 30 days, driven by a powerful rotation into biotechnology stocks and a resurgence in mergers and acquisitions (M&A) activity. The equal-weighted structure of the fund amplified gains across small- and mid-cap biotech names, rather than concentrating returns in a few large-cap holdings.

ARKG rose approximately 13% over the past 30 days, driven primarily by gains in key genomics and biotechnology holdings amid improving sector sentiment. Over the past quarter, ARKG advanced roughly 28%, reflecting broader recovery in healthcare innovation themes and positive momentum in gene-editing and sequencing companies.

XLV is in a short-term downtrend with a strong sell technical rating from moving averages and oscillators. Price is consolidating near recent lows around 144-145, below key moving averages including the 20-day at 145.94 and 200-day at 147.23.

IHI declined approximately -8.5% over the past 30 days amid softer demand for medical devices and broader healthcare sector pressures. Over the past quarter, the ETF fell around -15%, underperforming the broader health category due to valuation adjustments and muted procedural volumes.

Top hedge funds like Millennium, Citadel, and Bridgewater showed limited direct accumulation of penny stocks in Q4 2025 13F filings, but rotations into biotech, energy, and defense sectors highlight indirect interest in low-priced plays under $5. New entries and increased positions focused on volatile sectors like biotech (e.g., ABCL) and energy (e.g., AMPY), with full exits from overvalued names signaling a hunt for undervalued pennies amid market uncertainty.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a clinical-stage biopharmaceutical company focused on innovative cancer therapies, has captured the attention of investors with a staggering 251.95% stock price surge over the past five trading days as of July 22, 2025, accompanied by an average daily trading volume of 1 million shares.

Tickeron launches AI-powered Stock Picker robots to assist hedge fund managers with sector rotation, growth-focused small-cap stocks, and strategic risk management. Using proprietary FLMs, Stock Pickers offer quant-driven signals and adaptive strategies for long-term growth and investment

The current health crisis has created a lot of buzz around the biotech sector as several companies from the sector are working on potential vaccines against the COVID-19 virus.Many of the companies are overvalued at this time, but the fundamentals of many are really good. I looked at the SPDR S&P Biotech ETF (NYSE: XBI) and its components.

The biotech sector has been trending lower for the last five months, but has seen a bit of a rally over the last few weeks as investors appear to be making a shift from growth stocks to value stocks.Because of this rotation, many stocks in the sector are in overbought territory, at least on the daily charts.

The healthcare sector has been lagging the nine other main sectors since the beginning of 2019.The sector has been in the political spotlight to some degree as politicians on both sides of the aisle have been pointing at drug costs as a problem. One particular exchange-traded fund that caught my eye was the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB).

Are You? Also in this newsletter Healthcare sector ETF (XLV) trending lower since November A.I.It means evaluating myriad variables – post-retirement lifestyle, where to retire, cost of living, the rate of inflation, and more – then formulating a plan that considers current earnings and standard of living, in addition to… Read More… —————————————————————————————— Healthcare sector ETF (XLV) trending lower since November The overall market recovered from the selling that hit in December and that led the S&P 500 to a new all-time high on May 1.

The overall market recovered from the selling that hit in December and that led the S&P 500 to a new all-time high on May 1.The Healthcare Select Sector SPDR (NYSE: XLV) peaked just above $90 back in November and it has yet to get back to that point. In fact, if you connect the high from November with the highs from March and April, you can see the downward sloped trend line the ETF has formed.

Five U.S. states filed lawsuits accusing Purdue Pharma of illegally marketing and selling opioids, escalating the wave of litigation over a nationwide abuse epidemic. Iowa, Kansas, Maryland, West Virginia and Wisconsin joined 39 states to file lawsuits targeting Purdue Pharma and its leaders, including former president Richard Sackler and his family.  Officials accused Purdue Pharma of repeatedly making false and deceptive claims that opioids, including OxyContin, were safe for a wide range of patients seeking to reduce pain.  Purdue Pharma called the new lawsuits “misleading attacks.” “These complaints are part of a continuing effort to try these cases in the court of public opinion rather than the justice system,” the Stamford, Connecticut-based company said.